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Abstract
Background
Polymerase chain reaction (PCR) has become a useful tool for the diagnosis of Trypano-
soma cruzi infection. The development of automated DNA extraction methodologies and
PCR systems is an important step toward the standardization of protocols in routine diagno-
sis. To date, there are only two commercially available Real-Time PCR assays for the rou-
tine laboratory detection of T. cruzi DNA in clinical samples: TCRUZIDNA.CE (Diagnostic
Bioprobes Srl) and RealCycler CHAG (Progenie Molecular). Our aim was to evaluate the
RealCycler CHAG assay taking into account the whole process.
Methodology/Principal findings
We assessed the usefulness of an automated DNA extraction system based on magnetic
particles (EZ1 Virus Mini Kit v2.0, Qiagen) combined with a commercially available Real-
Time PCR assay targeting satellite DNA (SatDNA) of T. cruzi (RealCycler CHAG), a meth-
odology used for routine diagnosis in our hospital. It was compared with a well-known strat-
egy combining a commercial DNA isolation kit based on silica columns (High Pure PCR
Template Preparation Kit, Roche Diagnostics) with an in-house Real-Time PCR targeting
SatDNA. The results of the two methodologies were in almost perfect agreement, indicating
they can be used interchangeably. However, when variations in protocol factors were
applied (sample treatment, extraction method and Real-Time PCR), the results were less
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convincing. A comprehensive fine-tuning of the whole procedure is the key to successful
results. Guanidine EDTA-blood (GEB) samples are not suitable for DNA extraction based
on magnetic particles due to inhibition, at least when samples are not processed
immediately.
Conclusions/Significance
This is the first study to evaluate the RealCycler CHAG assay taking into account the overall
process, including three variables (sample treatment, extraction method and Real-Time
PCR). Our findings may contribute to the harmonization of protocols between laboratories
and to a wider application of Real-Time PCR in molecular diagnostic laboratories associated
with health centers.
Introduction
Chagas disease, a parasitic infection caused by the protozoan Trypanosoma cruzi, is endemic
in 21 countries of Latin America, with approximately six million people affected [1]. Migratory
flows have expanded Chagas disease worldwide, especially since the beginning of 2000, and the
disease has emerged in non-endemic countries of North America, Europe and the Western
Pacific Region [2,3].
In endemic settings the parasite is mainly transmitted by blood-sucking triatomine bugs
[4,5], whereas in areas without vector-borne exposure the risk of developing T. cruzi infection
arises from congenital transmission, blood transfusion, organ transplant, and laboratory acci-
dents [6,7]. The disease has two stages: acute and chronic. Although both can be asymptom-
atic, the chronic phase is usually associated with cardiac and gastrointestinal disorders as well
as low and intermittent parasitemia [8,9].
Several studies carried out in Spain and other parts of Europe have reported that screening
for Chagas disease and early diagnosis is cost-effective [10–12]. However, a large number of
patients in both endemic and non-endemic countries are still diagnosed late or not at all.
Therefore, there is an urgent need to establish an efficient diagnostic strategy to deal with T.
cruzi infection [13].
The serological diagnosis for Chagas disease is often difficult to interpret and although the
use of a single test has been recently proposed [14], there is still no reference standard [15].
Serological methods are currently widely used, especially in the chronic phase, and dozens of
tests are commercially available [16–19]. Nevertheless, serological diagnosis has certain disad-
vantages: the persistence of positive results in chronically infected patients for years after treat-
ment [20], the possibility of cross-reactions with other trypanosomatids like Trypanosoma
rangeli or Leishmania spp. [21], and the transmission of passive antibodies from mother to
newborn [22–24].
Molecular biology techniques, especially the polymerase chain reaction (PCR), have been
proposed as useful tools for the diagnosis of T. cruzi infection [25,26]. Unlike the serology test,
a positive PCR result confirms the presence of the parasite DNA. Moreover, the high sensitiv-
ity of PCR in comparison with classical parasitological techniques is particularly useful for an
early diagnosis of congenital cases [27–29].
Molecular detection of T. cruzi is also important in the chronic phase, as it can detect the
therapeutic failure of anti-parasitic treatments and parasite reactivation in patients with
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immunosuppression [30,31]. Furthermore, the PCR variant known as quantitative Real-Time
PCR also quantifies the amplification product using intercalating dyes or labeled probes and
standard curves of known parasite concentration [32]. The main problem with this approach
stems from the lack of consensus among laboratories on the PCR strategies used.
The recent development of automated DNA extraction methodologies coupled to PCR sys-
tems is an important step toward protocol standardization, while also preventing contamina-
tion of samples and reagents due to human manipulation. Automated nucleic acid extraction
systems are usually based on magnetic separation, a time-saving technology in comparison
with silica column-based DNA extractions [33,34]. One of the most applied molecular proto-
cols is the amplification of satellite DNA (SatDNA) of T. cruzi [35,36]. SatDNA is the most
abundant repetitive sequence in the parasite nuclear genome and is composed of about 105
copies of a 195 nucleotide repeat [37,38].
To date, there are only two commercially available Real-Time PCR assays for the diagnosis
of T. cruzi infection: TCRUZIDNA.CE (Diagnostic Bioprobes Srl, Sesto San Giovanni, Italy)
and RealCycler CHAG (Progenie Molecular, Valencia, Spain). Both amplify the SatDNA
sequence of T. cruzi. Seiringer et al. [39] recently evaluated TCRUZIDNA.CE but RealCycler
CHAG has not been assessed until now, and no studies have previously evaluated these T.
cruzi Real-Time PCR assays combined with different DNA extraction methods.
The aim of the present study was to assess the usefulness of an automated DNA extraction
system based on magnetic particles (EZ1 Virus Mini Kit v2.0, Qiagen, Hilden, Germany) com-
bined with a commercially available Real-Time PCR assay that targets the SatDNA of T. cruzi
(RealCycler CHAG), a methodology routinely used for T. cruzi-infection diagnosis in the Hos-
pital de la Santa Creu i Sant Pau of Barcelona (Spain). This technique was compared with a
well-known and widely used strategy combining a commercial DNA isolation kit based on sil-
ica columns (High Pure PCR Template Preparation Kit, Roche Diagnostics, Mannheim, Ger-
many) with an in-house Real-Time PCR that also targets the parasite SatDNA sequence [36].
Materials and methods
Ethics statement
Approval was obtained from the participating centers, the Clinical Research Ethics Committee
of the Hospital de la Santa Creu i Sant Pau, the Ethics Review Committee of the Hospital Clı´nic
and the Research Ethics Committee of the Universitat de Barcelona. All samples were anon-
ymized before being evaluated and included in the study.
Samples and population
A total of 123 blood samples were used in this study. Samples were collected from Hospital de
la Santa Creu i Sant Pau and Hospital Clı´nic of Barcelona (Spain) during the period from Janu-
ary 2013 to March 2017. EDTA-blood (EB) and EDTA-blood mixed with an equal volume of
guanidine hydrochloride solution 6 M (GEB) were obtained. Since the samples in the study
were obtained retrospectively, in some cases only one of the two options, EB or GEB, was avail-
able. EB samples were stored at -40˚C and GEB samples at 4˚C until the subsequent analysis.
Sample distribution was as follows: 19 from non-infected newborns from chagasic mothers, 5
from non-chagasic adults from endemic countries, 12 from non-chagasic individuals from
non-endemic countries, 65 from non-treated chronic chagasic patients, and 22 seronegative
GEB samples experimentally spiked with cultured epimastigotes of T. cruzi stocks as well as
non-spiked GEB samples. Sample results were defined in the following way: non-infected new-
borns from chagasic mothers were followed up by serology until their negativization within
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the first year of life, non-chagasic adults were those with negative serology, and chronic chaga-
sic patients were serologically positive by at least two different immunological techniques.
DNA extraction procedures
Two different methodologies were used for the DNA extraction.
(i) Silica gel columns–High Pure PCR Template Preparation Kit (Roche Diagnostics). The
protocol is available online at https://lifescience.roche.com. DNA extraction was performed
according to the manufacturer’s instructions. DNA was extracted from 200 μL of EB or 300 μL
of GEB and eluted in 100 μL of the elution buffer supplied with the kit, as previously described
[40]. The extracted DNA was stored at -40˚C until its analysis.
(ii) Magnetic particles–EZ1 Virus Mini Kit v2.0 (Qiagen). The protocol is available online
at https://www.qiagen.com. DNA extraction was performed according to the manufacturer’s
instructions using the EZ1 Advanced automated system based on magnetic particles. DNA
was extracted from 400 μL of EB or GEB samples and eluted in 60 μL of the AVE buffer sup-
plied with the kit. The extracted DNA was stored at -40˚C until its analysis. EB samples were
pre-treated with an equal volume of the erythrocyte lysis buffer (EL) (Qiagen), and 400 μL of
the mixture was then introduced to the EZ1 device. GEB samples were directly loaded into the
system.
For quantification, standard curves were built using non-chagasic human EB and GEB
spiked with cultured epimastigotes of the T. cruzi Maracay strain (TcI), giving a final concen-
tration of 106 parasite equivalents/mL (par. eq./mL). DNA from spiked blood used to construct
the standard curve was extracted with the High Pure PCR Template Preparation Kit and EZ1
Virus Mini Kit v2.0, and 1/10 serial dilutions of the DNA extracted in total blood DNA extrac-
tions from non-chagasic individuals were carried out in order to obtain a panel of samples
ranging from 105 to 1 par. eq./mL.
Real-Time PCR methods
Two Real-Time PCR procedures were performed.
(i) In house Real-Time PCR targeting the T. cruzi SatDNA. Five μL of the DNA eluates in a
final volume of 20 μL were amplified in triplicate. The final concentrations were: 1 x FastStart
Universal Probe Master (Rox) (Roche Diagnostics), 0.75 μM of each primer Cruzi 1 and
Cruzi 2, 0.25 μM of the probe Cruzi 3, and 0.2 x TaqMan Human RNase P detection reagent
(Applied Biosystems, Austin, TX) [36]. The reaction was carried out in an ABI7900 device
(Applied Biosystems) and the amplification of the RNase P human gene was included as an
internal amplification control (IAC) [36]. Amplification conditions were as follows: one step
of 10 min at 95˚C, and 40 cycles of 95˚C for 15 s, and 58˚C for 1 min [40]. A sample was con-
sidered valid when the RNase P human gene was efficiently amplified with a cycle threshold
value (Ct)29, which was established with the Tukey criterion to detect outliers [41,42]. Sam-
ples were classified as inhibited when the IAC gave negative results or the Ct was >29. A sam-
ple was considered positive when the Ct of the target was40 in at least one of the three
replicates.
(ii) RealCycler CHAG (Progenie Molecular). The test was carried out according to the man-
ufacturer’s instructions using the SmartCycler Automated Real-Time PCR system (Cepheid,
Sunnyvale, CA). The kit includes the CHAG AmpliMix, which contains all the reagents neces-
sary for the amplification as well as the IAC. The Real-Time PCR procedure was performed in
25 μL reaction volume containing 7.5 μL of eluted DNA and a single replica per sample was
amplified. According to the manufacturer’s specifications, amplification conditions were as
follows: one step of 15 min at 95˚C, and 45 cycles of 95˚C for 15 s, 60˚C for 30 s, and 72˚C for
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30 s. A sample was considered valid when the IAC was amplified with a Ct35 and inhibited
when the criterion was not fulfilled. A sample was considered positive when the Ct of the target
was40.
Experimental procedures
Sample treatments (EB and GEB), DNA extraction methods (silica columns and magnetic par-
ticles), and Real-Time PCR procedures (In house Real-Time PCR and RealCycler CHAG) were
combined to create eight different methodological protocols for assessment (Table 1).
The in house protocol A was considered the reference standard due to its validation in pre-
vious international studies [26,42] and the commercialized protocol H is used for T. cruzi rou-
tine diagnosis in the Hospital de la Santa Creu i Sant Pau.
Data analysis
Taken as the reference standard, protocol A was compared with all the others (B to H), result-
ing in seven possible combinations (A-B, A-C, A-D, A-E, A-F, A-G, and A-H). Protocols were
also compared by focusing on only one variable of the process: sample treatments, DNA
extraction methods or Real-Time PCR procedures. In this way, 12 combinations were created:
A-E, B-F, C-G, and D-H comparing sample treatments; A-C, B-D, E-G, and F-H comparing
DNA extraction methods; and A-B, C-D, E-F, and G-H comparing Real-Time PCR proce-
dures. For the protocol comparisons, Cohen’s kappa coefficient (K), which describes the level
of concordance between two tests relating the observed agreement and the agreement expected
by chance, was calculated for each protocol combination created. The interpretation of K val-
ues was as follows: 0 to 0.20 indicates slight agreement, 0.21 to 0.40 fair agreement, 0.41 to 0.60
moderate agreement, 0.61 to 0.80 substantial agreement, and 0.8 to 1 almost perfect agreement
[43]. Calculations were performed with the software EPIDAT 3.1, which is available online at
http://www.sergas.es/Saude-publica.
Parasitic loads obtained from positive samples in protocols A and H were compared in a
Bland-Altman difference plot in order to quantify the agreement between the two methods
[44]. The Spearman rank correlation coefficient (rs), which describes the strength of a mono-
tonic relationship between paired data, was also calculated [45]. Ranging from -1.0 to +1.0, val-
ues close to +1.0 indicate positive association whereas values close to -1.0 indicate negative
association. The interpretation of the absolute value of rs is as follows: 0 to 0.19 indicates a very
Table 1. Trypanosoma cruzi diagnostic Real-Time PCR results of samples analysed according to the protocols used in the study based on the combination of differ-
ent sample treatments, DNA extraction methods and Real-Time PCR procedures.
Protocol code Sample treatment DNA extraction method Real-Time PCR N Positive samples Inhibited samples N excluding inhibition
A (ref.) GEB Roche silica columns In house 123 72 0 123
B GEB Roche silica columns RealCycler 123 58 0 123
C GEB Qiagen magnetic particles In house 62 8 35 27
D GEB Qiagen magnetic particles RealCycler 62 25 17 45
E EB Roche silica columns In house 25 11 0 25
F EB Roche silica columns RealCycler 25 11 0 25
G EB Qiagen magnetic particles In house 64 15 2 62
H EB Qiagen magnetic particles RealCycler 64 15 0 64
Inhibited samples had negative results or a cycle threshold (Ct) value >29 for the internal amplification control in protocols using in house Real-Time PCR (A, C, E, and
G), and negative results or Ct >35 in protocols using RealCycler CHAG (B, D, F, and H).
Ref.: reference standard protocol, EB: EDTA-blood, GEB: Guanidine EDTA-blood, N: number of samples.
https://doi.org/10.1371/journal.pone.0195738.t001
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weak relationship, 0.20 to 0.39 weak, 0.40 to 0.59 moderate, 0.60 to 0.79 strong, and 0.80 to 1.0
a very strong relationship.
Results
A total of 123 blood samples were analyzed. Since this is a retrospective study, the number of
samples analyzed with each protocol is not identical (Table 1).
The results of the comparison between the reference protocol A and the others are summa-
rized in Table 2. K results are shown including and excluding inhibited samples. In protocols
using GEB samples a high level of inhibition was found when the DNA extraction method
based on magnetic particles was used, as shown in protocols C and D with 56.5% and 27.4% of
inhibition, respectively (Table 1). In the other cases, protocols did not present inhibition, with
the exception of protocol G (EB, magnetic particles and in house Real-Time PCR), which
yielded two inhibited samples (3.1%).
The number of discordant results between protocols ranged from 1 to 13. The results
obtained with these samples are listed in Table 3.
Protocols A (reference standard) and H (routine diagnosis in our hospital) gave matching
qualitative results for the 64 samples analysed (K = 1), 15 of which were positive. These proto-
cols also underwent a quantitative evaluation (Table 4). The level of agreement between the
positive samples in both methods is represented by a Bland-Altman difference plot (Fig 1).
The mean bias was determined as 0.12 Log10 par. eq./10 mL, indicating a systematic bias of
0.7-fold parasite equivalents per 10 mL between methods. The bias was in both directions and
did not differ in relation to the magnitude of the parasitic loads. However, samples with the
highest bias yielded very low parasitic loads (samples S2 and S11 in Table 4). Limits of agree-
ment were also included in the plot expressed as bias ± 1.96 x standard deviation (SD). The SD
was 0.43, the lower limit of agreement with a 95% confidence interval (CI) was -0.72 Log10 par.
eq./10 mL and the upper one was 0.96 Log10 par. eq./10 mL. The Spearman rank correlation
coefficient was rs = 0.97, which indicates very strong and positive correlation between
protocols.
Table 2. Cohen’s kappa coefficient (K) results for the comparison between the reference protocol A and the others. K values are shown including and excluding
inhibited samples.
Protocols N K value (95%
CI)
Positive
samples
Inhibited
samples
N excluding
inhibition
Discordant samples excluding
inhibition
K value excluding inhibited samples
(95% CI)
A-B 123 0.79
(0.68–0.9)
59 0 123 13 0.79 (0.68–0.9)
A-C 62 0.17
(0.08–0.26)
8 35 27 8 0.45 (0.18–0.72)
A-D 62 0.29
(0.14–0.44)
24 17 45 10 0.53 (0.3–0.77)
A-E 25 0.92
(0.77–1)
11 0 25 1 0.92 (0.77–1)
A-F 25 0.76
(0.5–1)
10 0 25 3 0.76 (0.5–1)
A-G 64 0.92
(0.81–1)
15 2 62 0 1
A-H 64 1 15 0 64 0 1
N: number of samples assessed in parallel by both protocols compared. Positive samples: number of samples with a positive result for both protocols. Inhibited samples:
number of samples with an invalid result for the internal amplification control (IAC) in at least one of the two protocols compared. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0195738.t002
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Protocols were also compared taking into account only one variable of the procedure
(Tables 5–7). K values and positive and inhibited sample results are shown for the following
variables: (i) sample treatment (Table 5); (ii) DNA extraction method (Table 6); and (iii) Real-
Time PCR procedures (Table 7). Modifications in one of the three variables resulted in
changes in the K values, the number of inhibited samples and the percentage of discordant
results obtained.
Table 3. Trypanosoma cruzi diagnostic Real-Time PCR results obtained in the eight protocols assessed for the 22 discordant samples.
Sample ID Protocolsa
A B C D E F G H
S1 N N N N N P (40)
1/1
N N
S2 P (32.2)
3/3
P (32.2)
1/1
P (29)
3/3
P (31.9)
1/1
P (31.9)
3/3
N P (32.9)
3/3
P (35)
1/1
S3 N N N P (40)
1/1
N N N N
S4 P (28.2) 3/3 P (30.5)
1/1
N P (28.3)
1/1
P (36.2)
3/3
P (39.5)
1/1
P (25.8)
3/3
P (28.5)
1/1
S5 P (29.6)
3/3
P (30.6)
1/1
P (28.5)
3/3
P (31.2)
1/1
N N P (26.9)
3/3
P (30.6)
1/1
S6 P (35.1)
1/3
N I I - - - -
S7 P (32.2) 2/3 N I P (34.2)
1/1
- - - -
S8 P (35.3)
1/3
N I N - - - -
S9 P (29.9)
3/3
P (34.1)
1/1
N P (32.2)
1/1
- - - -
S10 P (36.4) 1/3 N N N - - - -
S11 P (35.5)
1/3
N I N - - - -
S12 P (29.4) 3/3 P (31.8)
1/1
N P (31.2)
1/1
- - - -
S13 P (35.6) 1/3 N N N - - - -
S14 P (35)
1/3
N I I - - - -
S15 P (36.3)
1/3
P (38.4)
1/1
I N - - - -
S16 P (35.9) 1/3 N N N - - - -
S17 P (33.4)
2/3
N I I - - - -
S18 P (34.9) 2/3 N I N - - - -
S19 P (33.7) 1/3 N I I - - - -
S20 P (34.6) 1/3 P (39.7)
1/1
I N - - - -
S21 P (35.4) 1/3 N N I - - - -
S22 P (35.4) 1/3 N N N - - - -
Protocols A, C, E, and G used the in house Real-Time PCR with three replicates per sample. Protocols B, D, F, and H used RealCycler CHAG Real-Time PCR with a
single replica amplification per sample.
aCycle threshold (Ct) results are shown in parentheses. In case of multiple positive replicates, the mean of the Cts obtained is indicated. The number of positive
replicates is expressed as a fraction below.
P: positive, N: negative, I: inhibited.
https://doi.org/10.1371/journal.pone.0195738.t003
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Discussion
New strategies for Chagas disease diagnosis have been proposed with the introduction of com-
mercially available tests. Their implementation should bring about a considerable improve-
ment in the diagnosis of T. cruzi infection and lead to the standardization of protocols between
Table 4. Quantitative evaluation (parasitic load) of the 15 samples positive in protocols A (reference standard)
and H (Hospital de la Santa Creu i Sant Pau routine diagnosis).
Protocol A Protocol H
Sample ID Par. eq./mL Log10 Par. eq./10 mL Par. eq./mL Log10 Par. eq./10 mL
S1 0.47 0.67 0.28 0.45
S2 1.26 1.1 0.13 0.11
S3 51.80 2.71 24.79 2.39
S4 4.30 1.63 8.50 1.93
S5 21.90 2.34 21.55 2.33
S6 47.80 2.68 54.09 2.73
S7 12.49 2.1 6.43 1.81
S8 22.39 2.35 40.88 2.61
S9 331.00 3.52 395.66 3.6
S10 0.09 -0.05 0.03 -0.5
S11 0.39 0.59 0.04 -0.4
S12 1.94 1.29 5.21 1.72
S13 3.09 1.49 4.18 1.62
S14 1.14 1.06 0.94 0.97
S15 3.44 1.54 6.43 1.81
Parasitic loads are expressed in parasite equivalents in one mL of blood (Par. eq./mL) and in logarithms of the
parasite equivalents in 10 mL of blood (Log10 Par. eq./10 mL).
https://doi.org/10.1371/journal.pone.0195738.t004
Fig 1. Degree of agreement between protocols A and H based on a Bland-Altman plot of the nine samples with
quantifiable results in both methods. Each sample is represented by plotting the mean of the measurements obtained
in protocols A and H on the x-axis and the difference of the same two values on the y-axis. SD: standard deviation.
Log10 par. eq./10 mL: logarithmic values of parasite equivalents in 10 mL of blood.
https://doi.org/10.1371/journal.pone.0195738.g001
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laboratories. Regarding molecular tests, to our knowledge only two Real-Time PCR assays
(TCRUZIDNA.CE and RealCycler CHAG) are commercially available for the routine labora-
tory detection of T. cruzi DNA in clinical samples, both developed in Europe. Seiringer et al.
[39] have recently assessed TCRUZIDNA.CE, which showed high sensitivity and specificity
when compared with widely used PCR and Real-Time PCR strategies [26,46–48]. The study,
performed in Italy, evaluated the PCR amplification but not the sample treatment or the
extraction method. On the other hand, the RealCycler CHAG has not yet been assessed by
comparison with other PCR assays, as recommended [30]. Thus, the aim of the work presented
here was to assess this Real-Time PCR system taking into account the sample treatment and
DNA extraction method, and is therefore the first study to evaluate the overall process includ-
ing these three variables.
First of all, we created a panel of eight different protocols (Table 1) through the combina-
tion of three factors (sample treatments, DNA extraction methods, and Real-Time PCR proce-
dures) and compared each one with the protocol considered the reference standard (protocol
A in Table 1). All combinations reached a high concordance level except when the standard
was compared with protocols starting from GEB and using the DNA extraction method based
on magnetic particles (protocols C and D), which showed a high level of inhibition (Tables 1
and 2). A possible explanation is that the magnetic particle DNA isolation system was unable
Table 5. Cohen’s kappa coefficient (K) results for the comparison between protocols with the sample treatment as the only variable. K values are shown including
and excluding inhibited samples.
Protocols N K value (95%
CI)
Positive
samples
Inhibited
samples
N excluding
inhibition
Discordant samples excluding
inhibition
K value excluding inhibited samples
(95% CI)
A-E 25 0.92
(0.77–1)
11 0 25 1 0.92 (0.77–1)
B-F 25 0.76
(0.5–1)
10 0 25 3 0.76 (0.5–1)
C-G 25 0.45
(0.25–0.65)
5 8 17 1 0.87 (0.61–1)
D-H 25 0.55
(0.32–1)
7 6 19 1 0.89 (0.68–1)
N: number of samples assessed in parallel by both protocols compared. Positive samples: number of samples with a positive result for both protocols. Inhibited samples:
number of samples with an invalid result for the internal amplification control (IAC) in at least one of the two protocols compared. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0195738.t005
Table 6. Cohen’s kappa coefficient (K) results for the comparison between protocols with the DNA extraction system as the only variable. K values are shown
including and excluding inhibited samples.
Protocols N K value (95%
CI)
Positive
samples
Inhibited
samples
N excluding
inhibition
Discordant samples excluding
inhibition
K value excluding inhibited samples
(95% CI)
A-C 62 0.17
(0.08–0.26)
8 35 27 8 0.45 (0.18–0.72)
B-D 62 0.46
(0.31–0.61)
23 17 45 4 0.82 (0.65–0.99)
E-G 25 0.92
(0.77–1)
11 0 25 1 0.92 (0.77–1)
F-H 25 0.76
(0.5–1)
10 0 25 3 0.76 (0.5–1)
N: number of samples assessed in parallel by both protocols compared. Positive samples: number of samples with a positive result for both protocols. Inhibited samples:
number of samples with an invalid result for the internal amplification control (IAC) in at least one of the two protocols compared. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0195738.t006
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to completely eliminate the guanidine hydrochloride during the extraction process and the
residual solution in the extracted DNA inhibited the PCR [35,49]. An alternative explanation
is an excess of guanidine hydrochloride, given that some buffers of the kit reagent cartridges
already contain guanidine salts. Indeed, all extracted DNA from inhibited samples showed a
yellowish coloration, which was an early indication that the process had not worked properly.
Moreover, it was noted that inhibition was related to the time elapsed between the sample
treatment with guanidine and the DNA extraction: all inhibited samples were processed at
least six months before being mixed with guanidine. In contrast, no inhibition was observed
when DNA extraction occurred within the first week after the guanidine treatment. In the EB
samples practically no inhibition occurred; the two exceptional samples (out of 64) had under-
gone magnetic particle DNA extraction (protocol G), and there was probably a residual pool
of magnetic particles in the extracted DNA [50].
In this study, the RNase P human gene was used as an IAC to detect inhibition of the in
house Real-Time PCR, as previously described by Piro´n et al. [36]. However, we observed that
patients with leukopenia or neutropenia showed later Ct values in the Real-Time PCR than
immunocompetent individuals, rather than inhibition, as a consequence of their immunologi-
cal condition. This should therefore be born in mind when hematological patients are included
in studies of this kind. In fact, Duffy et al. [40] suggested the use of a heterologous extrinsic
IAC, which has subsequently been taken up in other studies [42,51,52]. Likewise, the RealCy-
cler assay includes this kind of control among the reagents supplied with the kit.
Once the inhibited samples were excluded from the analysis, discordant results appeared
with regard to the extraction method and the number of replicates amplified in the Real-Time
PCR. When comparing the reference protocol with those using GEB and magnetic particle
DNA extraction (Table 2), the results suggest that silica column-based DNA extraction works
more efficiently than the magnetic particle system with GEB samples. In contrast, the two
DNA extraction methodologies presented similar results with EB samples (Table 6). Taking
into account the number of replicates amplified in the Real-Time PCR, protocols using the
RealCycler Real-Time PCR included only one reaction of amplification per sample instead of
three, thus reducing the possibility of obtaining a positive result (Table 3). An increase in the
number of replicates in these protocols would probably reduce conflicting results. Otherwise
there were no important differences in results between protocols when comparing Real-Time
PCRs (Table 7), which could be expected since both target the parasite SatDNA and probably
use the same primer and probe sequences. However, the commercial formulation of the Real-
Cycler CHAG assay is not known.
Table 7. Cohen’s kappa coefficient (K) results for the comparison between protocols with the Real-Time PCR procedure as the only variable. K values are shown
including and excluding inhibited samples.
Protocols N K value (95%
CI)
Positive
samples
Inhibited
samples
N excluding
inhibition
Discordant samples excluding
inhibition
K value excluding inhibited samples
(95% CI)
A-B 123 0.79 (0.68–
0.9)
59 0 123 13a 0.79 (0.68–0.9)
C-D 62 0.44 (0.29–
0.6)
8 35 27 4 0.68 (0.41–0.96)
E-F 25 0.84 (0.62–1) 10 0 25 2 0.84 (0.62–1)
G-H 64 0.92 (0.81–1) 15 2 62 0 1
aNone of these samples were positive in all three replicates.
N: number of samples assessed in parallel by both protocols compared. Positive samples: number of samples with a positive result for both protocols. Inhibited samples:
number of samples with an invalid result for the internal amplification control (IAC) in at least one of the two protocols compared. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0195738.t007
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The results obtained highlight the importance of fine-tuning the overall process, including
sample treatment, DNA extraction method and Real-Time PCR, for the successful diagnosis of
T. cruzi infection. The reference standard protocol (A) and the one used for routine diagnosis
in our hospital (H) were in perfect concordance, but the results were less convincing when fac-
tor variations were introduced (Table 2).
The quantitative analysis was only performed for protocols A and H because their compari-
son was the only one to show perfect agreement and no inhibition. The 15 samples positive
with both protocols belonged to chronic patients, which probably explains why five samples
had very low parasitic loads (samples S1, S2, S10, S11, and S14 in Table 4). The number of sam-
ples in our study was a limiting factor for the analysis of the results. According to Bland and
Altman [44], some lack of agreement between different methods of measurement is inevitable,
therefore what is important is the amount by which methods disagree. Based on this assump-
tion, a Bland-Altman plot was constructed (Fig 1). As can be seen from the plot, the bias is not
statistically significant, so protocols A and H were determined as equivalent and interchange-
able [53].
Conclusions
The reference protocol (A) and the one used for routine molecular diagnosis of T. cruzi DNA
in our hospital (H) were in perfect concordance and both tests can be used interchangeably.
Therefore, protocol H (EB samples, EZ1 Virus Mini Kit v2.0 and the RealCycler CHAG) is a
good option for the routine diagnosis of T. cruzi infection. The combination of these two
assays allows results to be obtained in just over two hours, in a straightforward way and with
minimum handling, which indicates its suitability for incorporation in hospital-associated lab-
oratories. When variations in protocol factors were applied, the results were less convincing,
which highlights that the overall process needs to be fine-tuned to obtain good results. The
large number of inhibited GEB samples detected indicates they are not suitable for the DNA
extraction method based on magnetic particles, at least when samples are not processed
immediately.
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